HER2-NEGATIVE BREAST CANCER
Clinical trials for HER2-NEGATIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-NEGATIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-NEGATIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New chemo combo shows promise in breast cancer trial
Disease control CompletedThis study tested a new chemotherapy drug called WH002 against the standard drug paclitaxel in 40 women with HER2-negative breast cancer. Both drugs were given before surgery, followed by two other chemotherapy drugs. The main goal was to compare side effects and how well the tum…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Beijing Wehand-Bio Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New combo therapy for advanced breast cancer shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called ONO-4578 combined with standard hormone therapy and targeted drugs (letrozole plus palbociclib or abemaciclib) in 46 postmenopausal women with advanced or recurrent hormone receptor-positive, HER2-negative breast cancer. The main go…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New pill shows promise against tough breast cancer
Disease control CompletedThis study tested a new oral drug called OP-1250 in 153 adults with advanced or metastatic hormone-receptor-positive, HER2-negative breast cancer. The drug works by blocking estrogen receptors more completely than current therapies. The trial aimed to find the best dose, check sa…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Olema Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New test may predict which breast cancer patients benefit from targeted drug
Disease control CompletedThis study looked at whether a test called RAD51-foci can predict how well the drug olaparib works in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). About 65 participants received olaparib, and researcher…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: SOLTI Breast Cancer Research Group • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for breast cancer: personalized Pre-Surgery drug combo shows promise
Knowledge-focused CompletedThis study looked at whether adding a drug that targets specific genetic changes in breast tumors could slow cancer growth more than standard hormone therapy alone. It involved 19 people with ER-positive, HER2-negative breast cancer who received treatment before surgery. The goal…
Matched conditions: HER2-NEGATIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Jennifer Lee Caswell-Jin • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC